share_log

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

贝尔德维持EyePoint制药的跑赢大盘,将目标股价下调至38美元
Benzinga ·  05/08 07:02

Baird maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and lowers the price target from $46 to $38.

贝尔德维持EyePoint制药公司(纳斯达克股票代码:EYPT)的跑赢大盘,并将目标股价从46美元下调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发